naadp

Ca2+ mobilizing agent

NAADP sodium is a Ca2+ mobilizing second messenger that targets a novel Ca(2+) channel located on acidic organelles and indirectly activates TPC by binding to NAADP-binding proteins (NAADP-BPs) that form part of the TPC complex, which can be used to study cancer and immune dysfunction.F13714 fumarate is used in the study of leukemia.GSK321 is used in the study of leukemia.GSK321 is used in the study of leukemia.

NAADP tetrasodium is a second messenger that releases Ca2+ from acidic endosomes and lysosomes. It is used in the study of cancer, such as oral squamous cell carcinoma and malignant melanoma, as well as in research related to angiogenesis-associated diseases.

ε-NAADP+ is a fluorescent derivative of NAADP, known for inducing calcium mobilization. It effectively induces calcium release in sea urchin egg homogenates with an EC50 of 5 µM. The compound exhibits excitation and emission maxima at 275 nm and 410 nm, respectively. Notably, its emission intensity increases three-fold when dissolved in DMSO.

Ned 19, a selective membrane-permeant non-competitive antagonist of NAADP, strongly inhibits tumor growth, vascularization, and lung metastases in mice.

trans-Ned 19 is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist and two-pore channel (TPC) blocker. It binds with high affinity to the NAADP receptor to inhibit NAADP-dependent lysosomal/endolysosomal calcium release without affecting IP3 or cADPR-mediated calcium signaling pathways. Functionally, trans-Ned 19 inhibits glucose-induced calcium oscillations in pancreatic islets and low histamine concentration-induced endothelium-dependent vasodilation, and reduces Ebola virus infection of host cells. In immunomodulation, NAADP signaling blockade by trans-Ned 19 promotes the conversion of mouse Th17 cells to regulatory T cells (Tregs) and shows protective effects in intestinal inflammation models.

nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist

TPC2-A1-P is a membrane-permeable two-pore channel 2 (TPC2) agonist that differentially activates two-pore channel 2 (TPC2) and mimics the activation of TPC2 with NAADP and PIP(2). TPC2-A1-P can be used to study neurodegenerative lysosomal storage diseases.

Ned-K, a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist, exhibits inhibitory effects on myocardial ischemia and reperfusion (sIR)-induced calcium oscillations.

Thio-NADP (S-NADP) functions as an inhibitor of nicotinic acid adenine dinucleotide phosphate (NAADP) and induces partial Ca 2+ release [1].

PPADS is a P2 receptor antagonist with IC50 values of 68 nM (P2X1) and 214 nM (P2X3). This compound functions as an ATP (nucleotide) analog, competing for binding sites on the P2 receptors with ATP. Additionally, PPADS acts as a reversible competitive antagonist of the NAADP receptor. It is capable of reversing hyperalgesia, and it diminishes the enhanced NO/NOS signaling and IL-1β production in both peripheral and central steps of the nervous system.